Metabolic effects of long-term reduction in free fatty acids with acipimox in obesity: A randomized trial

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 3, 2016, Pages 1123-1133

  Makimura, Hideo ^a,b   Stanley, Takara L ^a,b   Suresh, Caroline ^a   De Sousa Coelho, Ana Luisa ^b,c   Frontera, Walter R ^d,e,f   Syu, Stephanie ^a   Braun, Laurie R ^a,b   Looby, Sara E ^a,b   Feldpausch, Meghan N ^a   Torriani, Martin ^a,b   Lee, Hang ^a,b   Patti, Mary Elizabeth ^b,c   Grinspoon, Steven K ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JOSLIN DIABETES CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

^f UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; ADIPONECTIN; CHOLESTEROL; CREATINE PHOSPHATE; FATTY ACID; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN; PLACEBO; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; GLUCOSE BLOOD LEVEL; PYRAZINE DERIVATIVE;

ADULT; ARTICLE; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; EXERCISE; FATTY ACID BLOOD LEVEL; FEMALE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; HUMAN TISSUE; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MALE; MUSCLE MITOCHONDRION; OBESITY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREND STUDY; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DOWN REGULATION; DRUG EFFECTS; LIPID METABOLISM; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; BLOOD GLUCOSE; BODY COMPOSITION; DOWN-REGULATION; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; MALE; MIDDLE AGED; OBESITY; PYRAZINES; YOUNG ADULT;

EID: 84960883859     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3696     Document Type: Article

References (57)

1. Brehm A. Acute elevation of plasma lipids does not affect ATP synthesis in human skeletal muscle. Am J Physiol Endocrinol Metab. 2010;299:E33-E38.
2. Brehm A, Krssak M, Schmid AI, Nowotny P, Waldhäusl W, Roden M. Increased lipid availability impairs insulin-stimulated ATP synthesis in human skeletal muscle. Diabetes. 2006;55(1):136-140.
3. Belfort R, Mandarino L, Kashyap S, et al. Dose-response effect of elevated plasma free fatty acid on insulin signaling. Diabetes. 2005; 54(6):1640-1648.
4. Bajaj M, Medina-Navarro R, Suraamornkul S, Meyer C, De Fronzo RA, Mandarino LJ. Paradoxical changes in muscle gene expression in insulin-resistant subjects after sustained reduction in plasma free fatty acid concentration. Diabetes. 2007;56(3):743-752.
5. Bajaj M, Suraamornkul S, Romanelli A, et al. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-Co As and insulin action in type 2 diabetic patients. Diabetes. 2005;54(11):3148-3153.
6. Fulcher GR, Catalano C, Walker M, et al. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus. Diabet Med. 1992;9(10):908-914.
7. Santomauro AT, Boden G, Silva ME, et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes. 1999;48(9):1836-1841.
8. Yu C, Chen Y, Cline GW, et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem. 2002;277(52):50230-50626.
9. Griffin ME, Marcucci MJ, Cline GW, et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C 0 and alterations in the insulin signaling cascade. Diabetes. 1999; 48(6):1270-1274.
10. Kruszynska YT, Worrall DS, Ofrecio J, Frias JP, Macaraeg G, Olef-sky JM. Fatty acid-induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation. J Clin Endocrinol Metab. 2002;87(1):226-234.
11. Koves TR, Li P, An J, et al. Peroxisome proliferator-activated re-ceptor-7 co-activator 1a-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J Biol Chem. 2005;280(39):33588-33598.
12. Koves TR, Ussher JR, Noland RC, et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 2008;7(1):45-56.
13. Stuyt PM, Kleinjans HA, Stalenhoef AF. Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia. Neth J Med. 1998;53(5):228-233.
14. Crepaldi G, Avogaro P, Descovich GC, et al. Plasma lipid lowering activity of acipimox in patients with type II and type IV hyperlipoproteinemia. Results of a multicenter trial. Atherosclerosis. 1988; 70:115-121.
15. Hadigan C, Liebau J, Torriani M, Andersen R, Grinspoon S. Improved triglycerides and insulin sensitivity with 3 months of acipimox in human immunodeficiency virus-infected patients with hypertriglyceridemia. J Clin Endocrinol Metab. 2006; 91(11):4438-4444.
16. Halbirk M, Nørrelund H, Møller N, et al. Suppression of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. Am J Physiol Heart Circ Physiol. 2010;299(4):H1220-H1225.
17. van de Weijer T, Phielix E, Bilet L, et al. Evidence for a direct effect of the NAD + precursor acipimox on muscle mitochondrial function in humans. Diabetes. 2015;64(4):1193-1201.
18. Daniele G, Eldor R, Merovci A, et al. Chronic reduction of plasma free fatty acid improves mitochondrial function and whole-body insulin sensitivity in obese and type 2 diabetic individuals. Diabetes. 2014;63(8):2812-2820.
19. Phielix E, Jelenik T, Nowotny P, Szendroedi J, Roden M. Reduction of non-esterified fatty acids improves insulin sensitivity and lowers oxidative stress, but fails to restore oxidative capacity in type 2 diabetes: a randomised clinical trial. Diabetologia.2014;57(3):572-581.
20. Montecucco F, Bertolotto M, Vuilleumier N, et al. Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome. Am J Physiol Endocrinol Metab. 2011;300(4): E681-E690.
21. Worm D, Henriksen JE, Vaag A, Thye-Rønn P, Melander A, Beck-Nielsen H. Pronounced blood glucose-lowering effect of the antili-polytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab. 1994;78(3):717-721.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
23. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21(12):2191-2192.
24. Hosseini Ghomi R, Bredella MA, Thomas BJ, Miller KK, Torriani M. Modular MR-compatible lower leg exercise device for whole-body scanners. Skeletal Radiol. 2011;40(10):1349-1354.
25. Hamarneh SR, Murphy CA, Shih CW, et al. Relationship between serum IGF-1 and skeletal muscle IGF-1 mRNA expression to phos-phocreatine recovery after exercise in obese men with reduced GH. J Clin Endocrinol Metab. 2015;100(2):617-625.
26. Roussel M, Bendahan D, Mattei JP, Le Fur Y, Cozzone PJ. 31P magnetic resonance spectroscopy study of phosphocreatine recovery kinetics in skeletal muscle: the issue of intersubject variability. Biochim Biophys Acta. 2000;1457:18-26.
27. Dietrichson P, Coakley J, Smith PE, Griffiths RD, Helliwell TR, Edwards RH. Conchotome and needle percutaneous biopsy of skeletal muscle. J Neurol Neurosurg Psychiatry. 1987;50(11): 1461-1467.
28. Bergstrom J. Percutaneous needle biopsy of skeletal muscle in physiological and clinical research. Scand J Clin Lab Invest. 1975;35(7): 609-616.
29. Evans WJ, Phinney SD, Young VR. Suction applied to a muscle biopsy maximizes sample size. Med Sci Sports Exerc. 1982;14(1): 101-102.
30. van Nimwegen LJ, Storosum JG, Blumer RM, et al. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab. 2008; 93(2):572-577.
31. Wang X, Patterson BW, Smith GI, et al. A ~60-min brisk walk increases insulin-stimulated glucose disposal but has no effect on hepatic and adipose tissue insulin sensitivity in older women. J Appl Physiol (1985). 2013;114(11):1563-1568.
32. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237:E214-E223.
33. Borkan GA, Gerzof SG, Robbins AH, Hults DE, Silbert CK, Silbert JE. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr. 1982;36(1):172-177.
34. Torriani M, Thomas BJ, Halpern EF, Jensen ME, Rosenthal DI, Palmer WE. Intramyocellular lipid quantification: repeatability with 1H MR spectroscopy. Radiology. 2005;236(2):609-614.
35. Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy X-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr. 1990;51(6):1106-1112.
36. Storlien L, Oakes ND, Kelley DE. Metabolic flexibility. Proc Nutr Soc. 2004;63(2):363-368.
37. Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol. 1999;277:E1130-E1141.
38. Kelley DE, Goodpaster BH, Storlien L. Muscle triglyceride and insulin resistance. Annu Rev Nutr. 2002;22:325-346.
39. Bouchard C, Tremblay A, Leblanc C, Lortie G, Savard R, Thériault G. A method to assess energy expenditure in children and adults. Am J Clin Nutr. 1983;37(3):461-467.
40. Sinnwell TM, Sivakumar K, Soueidan S, et al. Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy. J Clin Invest. 1995;96(1):126-131.
41. Dixon WJ. Analysis of extreme values. Ann Math Stat. 1950;421: 488-506.
42. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43-46.
43. Rothman KJ. Six persistent research misconceptions. J Gen Intern Med. 2014;29(7):1060-1064.
44. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726-732.
45. Turner N. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents. Diabetes. 2007;56:2085-2092.
46. Fillmore N, Jacobs DL, Mills DB, Winder WW, Hancock CR. Chronic AMP-activated protein kinase activation and a high-fat diet have an additive effect on mitochondria in rat skeletal muscle. J Appl Physiol. 2010;109(2):511-520.
47. Hancock CR. High-fat diets cause insulin resistance despite an increase in muscle mitochondria. Proc Natl Acad Sci USA. 2008;105: 7815-7820.
48. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999;103(2):253-259.
49. Zhou YP, Grill V. Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab. 1995;80(5):1584-1590.
50. Zhou YP, Grill VE. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest. 1994;93(2):870-876.
51. Befroy DE, Petersen KF, Dufour S, et al. Impaired mitochondrial substrate oxidation in muscle of insulin-resistant offspring of type 2 diabetic patients. Diabetes. 2007;56(5):1376-1381.
52. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and car-diometabolic disease. N Engl J Med. 2014;371(12):1131-1141.
53. Goldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials [published online September 14, 2015]. Heart. doi:10.1136/heartjnl-2015-308055.
54. Phan BA, Muñoz L, Shadzi P, et al. Effects of niacin on glucose levels, coronary stenosis progression, and clinical events in subjects with normal baseline glucose levels (<100 mg/dL): a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), HDL-Ath-erosclerosis Treatment Study (HATS), Armed Forces Regression Study (AFREGS), and Carotid Plaque Composition by MRI during lipid-lowering (CPC) study. Am J Cardiol. 2013; 111(3): 352-355.
55. Shah RV, Allison MA, Lima JA, et al. Liver fat, statin use, and incident diabetes: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2015;242(1):211-217.
56. Cederberg H, Stancáková A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015;58(5): 1109-1117.
57. Ridker PM, Pradhan A, Mac Fadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841): 565-571.